IXC
INVEX THERAPEUTICS LTD
$0.0850
0.00%
Market cap
$7M
Turnover
—
Last price
$0.0850
Day change
0.00%
Announcements
5
Range, past year
Open 0.120 · Low 0.075 · Now 0.085 · High 0.180
Open IXC in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
IXC momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
21/100
Wyckoff phase
Downtrend4d
Trend stage
Breakdown
1 Day
+0.0%
1 Week
-5.6%
1 Month
-19.0%
1 Year
-37.0%
RSI
29
Avg daily range
3.2%
INVEX THERAPEUTICS LTD scores 21 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 4 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- RSI oversold (29)
- 60d drawdown -34.6%
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsIXC announcements
Recent price-sensitive releases.
- 2026-10-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
- 2026-10-26 Invex to Acquire Rekover Therapeutics Placement | Asset Acquisition | Trading Halt Lifted | Director Appointment/Resignation
- 2026-10-22 Trading Halt Trading Halt
- 2026-08-31 Appendix 4E and Annual Report to shareholders Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-04-24 Quarterly Activities/Appendix 4C Cash Flow Report
More Health Care stocks
Most traded in the same sector.